ivermectin Side Effects
Also known as: Stromectol
Analysis of 5,936 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
5,936
Death-Related
540
9.1% of reports
Hospitalizations
2,144
36.1% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 540 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 99 |
| DRUG INEFFECTIVE | 81 |
| STRONGYLOIDIASIS | 61 |
| COMA | 55 |
| PYREXIA | 50 |
| SEPTIC SHOCK | 48 |
| ASTHENIA | 45 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 42 |
| OFF LABEL USE | 37 |
| SEPSIS | 37 |
| RESPIRATORY FAILURE | 32 |
| DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS | 31 |
| PNEUMONIA | 30 |
| DIARRHOEA | 24 |
| CONDITION AGGRAVATED | 23 |
| HEADACHE | 23 |
| ACUTE KIDNEY INJURY | 22 |
| HYPOTENSION | 21 |
| HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS | 20 |
| CARDIAC ARREST | 19 |
Reactions in Hospitalization Reports
Top reactions in 2,144 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| ASTHENIA | 538 |
| HEADACHE | 493 |
| PYREXIA | 426 |
| OCULAR HYPERAEMIA | 240 |
| CONJUNCTIVAL HAEMORRHAGE | 238 |
| COMA | 229 |
| BACK PAIN | 202 |
| DIARRHOEA | 202 |
| VERTIGO | 200 |
| ARTHRALGIA | 147 |
| GAIT DISTURBANCE | 144 |
| VOMITING | 143 |
| URINARY INCONTINENCE | 130 |
| ENCEPHALOPATHY | 124 |
| OFF LABEL USE | 111 |
| PRURITUS | 110 |
| MYALGIA | 105 |
| DRUG INEFFECTIVE | 102 |
| HYPOTENSION | 101 |
| DEPRESSED LEVEL OF CONSCIOUSNESS | 100 |
Nearby — Related Medications
What the FAERS Data Reveals About ivermectin Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 5,936 voluntary reports linked to ivermectin and its brand equivalents (Stromectol), spanning 2004 through 2025. Of those, 540 (9.1%) listed death as an outcome and 2,144 (36.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 52% were female and 47% male; age distribution skews toward 45-64, with 1,362 reports in that bracket. The single most reported reaction is drug ineffective with 728 submissions, followed by headache and asthenia.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.